Philip Morris International Inc. PM

Consumer staples SIC 2111 - Cigarettes NYSE

Philip Morris International Inc. is a Virginia holding company incorporated in 1987. In March 2008, we became a U.S. public company listed on the New York Stock Exchange and subject to the rules of the U.S. Securities and Exchange Commission (the "SEC"). We are a leading international consumer goods company, actively delivering a smoke-free future and evolving our portfolio for the long term to include products outside of the tobacco and nicotine sector. Our current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. Since 2008, we have invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This investment includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, we acquired Swedish Match AB ("Swedish Match") – a leader in oral nicotine delivery – creating a global smoke-free combination led by the companies' IQOS and ZYN brands. As of April 30, 2024, we hold the full rights to commercialize IQOS in the U.S. after reaching an agreement to end our U.S. commercial relationship covering IQOS with Altria Group, Inc. in 2022. Following a robust science-based review, the U.S. Food and Drug Administration (the "FDA") has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product ("MRTP") authorizations from the FDA. We describe the MRTP orders in more detail in the "Business Environment" section of Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Last close 182.53 2026-09-04
Market cap $284.49B 2026-06-30 share count
52-week range 142.11 - 207.76

Valuation FY2025 figures against the last close

P/S7.0x
P/E25.1x
P/FCF26.7x
EV/EBITDA16.6x
Dividend yield3.0%
Diluted EPS7.26

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $40.65B$37.88B$35.17B$31.76B$31.41B$28.69B$29.80B$29.62B$28.75B$26.68B
Cost of revenue $13.37B$13.33B$12.89B$11.40B$10.03B$9.57B$10.51B$10.76B$10.43B$9.39B
Gross profit $27.28B$24.55B$22.28B$20.36B$21.38B$19.12B$19.29B$18.87B$18.32B$17.29B
R&D $756.0M$759.0M$709.0M$642.0M$617.0M$495.0M$465.0M$383.0M$453.0M$429.0M
SG&A $164.0M$161.0M
Operating income $14.89B$13.40B$11.56B$12.25B$12.97B$11.67B$10.53B$11.38B$11.58B$10.90B
Interest expense $1.59B$1.76B$1.53B$768.0M$737.0M$728.0M$796.0M$855.0M$1.10B$1.07B
Pre-tax income $13.88B$12.20B$10.45B$11.63B$12.23B$10.95B$9.87B$10.67B$10.59B$9.92B
Income tax $2.74B$3.02B$2.34B$2.24B$2.67B$2.38B$2.29B$2.44B$4.31B$2.77B
Net income $11.35B$7.06B$7.81B$9.05B$9.11B$8.06B$7.18B$7.91B$6.04B$6.97B
EPS, basic 7.274.535.025.825.835.164.615.083.884.48
EPS, diluted 7.264.525.025.815.835.164.615.083.884.48
Shares, diluted (wtd. avg.) $1.56B$1.56B$1.55B$1.55B$1.56B$1.56B$1.56B$1.55B$1.55B$1.55B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $4.87B$4.22B$3.15B$3.22B$4.50B$7.29B$6.87B$6.62B$8.48B$4.33B
Receivables $4.57B$3.79B$3.46B$3.85B$3.12B$2.90B$3.08B$2.95B$3.19B$3.50B
Inventory $11.48B$9.45B$10.77B$9.89B$8.72B$9.59B$9.23B$8.80B$8.81B$9.02B
Total current assets $24.36B$20.17B$19.75B$19.62B$17.72B$21.49B$20.51B$19.44B$21.59B$17.61B
Property, plant and equipment $6.37B$6.63B$7.20B$7.27B$6.06B
Goodwill $17.26B$16.60B$16.78B$19.66B$6.68B$5.96B$5.86B$7.19B$7.67B$7.32B
Other intangibles $10.88B$11.33B$9.86B$6.73B$2.82B$2.02B$2.11B$2.28B$2.43B$2.47B
Total assets $69.19B$61.78B$65.30B$61.68B$41.29B$44.81B$42.88B$39.80B$42.97B$36.85B
Accounts payable $4.41B$3.95B$4.14B$4.08B$3.33B$2.78B$2.30B$2.07B$2.24B$1.67B
Short-term debt $168.0M$137.0M$1.97B$5.64B$225.0M$244.0M$338.0M$730.0M$499.0M$643.0M
Total current liabilities $25.43B$22.91B$26.38B$27.34B$19.25B$19.61B$18.83B$17.19B$15.96B$16.47B
Total liabilities $77.21B$71.65B$74.75B$67.99B$49.50B$55.45B$52.47B$50.54B$53.20B$47.75B
Retained earnings $35.40B$32.87B$34.09B$34.29B$33.08B$31.64B$30.99B$31.01B$29.86B$30.40B
Total equity -$9.99B-$11.75B-$9.45B-$6.31B-$8.21B-$10.63B-$9.60B-$10.74B-$10.23B-$10.90B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $12.23B$12.22B$9.20B$10.80B$11.97B$9.81B$10.09B$9.48B$8.91B$8.08B
Depreciation and amortisation $2.00B$1.79B$1.40B$1.08B$998.0M$908.0M$898.0M$907.0M$787.0M$669.0M
Capital expenditure $1.57B$1.44B$1.32B$1.08B$748.0M$602.0M$852.0M$1.44B$1.55B$1.17B
Investing cash flow -$3.97B-$1.09B-$3.60B-$15.68B-$2.36B-$1.15B-$1.81B-$998.0M-$3.08B-$834.0M
Financing cash flow -$8.13B-$9.48B-$5.58B$3.81B-$11.98B-$8.50B-$8.06B-$9.65B-$2.77B-$5.41B
Dividends paid $8.62B$8.20B$7.96B$7.81B$7.58B$7.36B$7.16B$6.88B$6.52B$6.38B
Buybacks $0$0$209.0M$775.0M$0$0$0$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-005939.

Others in SIC 2111

TickerCompanyMarket capP/ERevenue growth
MO ALTRIA GROUP, INC. $115.01B 16.7x -3.1%
ISPR Ispire Technology Inc. $88.4M -16.1%
XXII 22nd Century Group, Inc. $1.7M -27.9%
BTI British American Tobacco p.l.c.
RLX RLX Technology Inc. 50.3%